## Company Overview

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Boulder, Colorado, with manufacturing operations in Jalisco, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.

**Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income Tax**
Nov 10 2026, 4:10 PM EST

**Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA**
Aug 6 2026, 9:00 AM EDT

**Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution**
Jun 30 2026, 9:00 AM EDT

## Stock Overview

| | |
|---|---|
| Symbol | SNOA |
| Exchange | Nasdaq |
| Market Cap | 5.46m |
| Last Price | $1.14 |
| 52-Week | $0.8501 - $3.95 |

**11/10/2026 09:00 PM EST**

## Investor Relations

T: 470-938-1011
ir@sonomapharma.com

## Management Team

**Amy Trombly**
Chief Executive Officer

**Jerry Dvonch**
Chief Financial Officer

**Arturo Angel**
Senior Vice President of Regulatory, Quality and Product Development

## Sonoma Pharmaceuticals, Inc.

5445 Conestoga Court
Suite 150
Boulder, CO 80301

## Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and it's quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.